20 years of taxane therapy in prostate cancer - the past, present and future.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Nature reviews. Urology

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41585-025-01104-9PMID 41214336PMCID PMC12784451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

  2025cited by this paper
• Systematic profiling of Taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels

  2024cited by this paper
• Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

  2024cited by this paper
• Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

  2024cited by this paper
• Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

  2024cited by this paper
• Tumor ABCC4-mediated release of PGE2 induces CD8+ T cell dysfunction and impairs PD-1 blockade in prostate cancer

  2024cited by this paper
• Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer

  2024cited by this paper
• Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-κB activation and promotes docetaxel efficacy in prostate cancer

  2024cited by this paper
• The yin and yang of chromosomal instability in prostate cancer

  2024cited by this paper
• Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.

  2024cited by this paper
• B7-H3: a robust target for immunotherapy in prostate cancer.

  2024cited by this paper
• The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.

  2024cited by this paper
• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives

  2024cited by this paper
• Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer

  2024cited by this paper
• The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer

  2023cited by this paper
• Chemo-Immunotherapy: A New Trend in Cancer Treatment

  2023cited by this paper
• Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

  2023cited by this paper
• Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer

  2023cited by this paper
• Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.

  2023cited by this paper
• Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.

  2023cited by this paper
• Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

  2023cited by this paper
• Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

  2023cited by this paper
• Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer

  2023cited by this paper
• Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer.

  2023cited by this paper
• Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

  2022cited by this paper
• Specific MRP4 Inhibitor Ceefourin-1 Enhances Apoptosis Induced by 6-Mercaptopurine in Jurkat Leukemic Cells, but Not in Normal Lymphoblast Cell Line CRL-1991

  2022cited by this paper
• Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer

  2022cited by this paper
• PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

  2022cited by this paper
• Exploiting senescence for the treatment of cancer

  2022cited by this paper
• Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

  2022cited by this paper
• Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy

  2022cited by this paper
• Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.

  2022cited by this paper
• Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer

  2022cited by this paper
• Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.

  2022cited by this paper
• Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.

  2022cited by this paper
• Immunogenic cell stress and death

  2022cited by this paper
• Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker.

  2022cited by this paper
• Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.

  2022cited by this paper
• Cellular senescence: the good, the bad and the unknown

  2022cited by this paper
• βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies.

  2021cited by this paper
• Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial.

  2021cited by this paper
• Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.

  2021cited by this paper
• Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

  2021cited by this paper
• Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States

  2021cited by this paper
• Cancer metabolism: looking forward

  2021cited by this paper
• Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

  2021cited by this paper
• Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

  2021cited by this paper
• The human leukocyte antigen as a candidate tumor suppressor.

  2021cited by this paper
• Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer

  2021cited by this paper
• A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer

  2021cited by this paper
• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

  2020cited by this paper
• Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.

  2020cited by this paper
• The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

  2020cited by this paper
• Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

  2020cited by this paper
• Identification of a Zeb1 expressing basal stem cell subpopulation in the prostate

  2020cited by this paper
• Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer

  2020cited by this paper
• Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  2020cited by this paper
• HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression.

  2020cited by this paper
• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

  2020cited by this paper
• Cellular rewiring in lethal prostate cancer: the architect of drug resistance

  2020cited by this paper
• Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers

  2020cited by this paper
• Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance

  2020cited by this paper
• Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer

  2020cited by this paper
• Pembrolizumab for Early Triple-Negative Breast Cancer.

  2020cited by this paper
• Inhibition of Nuclear Pore Complex Formation Selectively Induces Cancer Cell Death.

  2020cited by this paper
• Mitotic slippage: an old tale with a new twist

  2019cited by this paper
• Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

  2019cited by this paper
• Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients

  2019cited by this paper
• Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer

  2019cited by this paper
• Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

  2019cited by this paper
• Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis

  2019cited by this paper
• Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

  2019cited by this paper
• Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

  2019cited by this paper
• ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

  2019cited by this paper
• A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

  2019cited by this paper
• Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.

  2019cited by this paper
• ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer.

  2019cited by this paper
• Revisiting the role of ABC transporters in multidrug-resistant cancer

  2018cited by this paper
• Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

  2018cited by this paper
• The long tail of oncogenic drivers in prostate cancer

  2018cited by this paper
• Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

  2018cited by this paper
• Microtubule-severing enzymes: From cellular functions to molecular mechanism

  2018cited by this paper
• Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

  2018cited by this paper
• Insulin‐like growth factor 2 expression in prostate cancer is regulated by promoter‐specific methylation

  2018cited by this paper
• Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

  2018cited by this paper
• RNA sequencing reveals upregulation of a transcriptomic program associated with stemness in metastatic prostate cancer cells selected for taxane resistance

  2018cited by this paper
• Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

  2018cited by this paper
• Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance

  2018cited by this paper
• Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

  2018cited by this paper
• Impact of taxanes on androgen receptor signaling

  2018cited by this paper
• Clinical implications of PTEN loss in prostate cancer

  2018cited by this paper
• A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

  2018cited by this paper
• The Influence of Metabolism on Drug Response in Cancer

  2018cited by this paper
• A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)

  2018cited by this paper
• Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer

  2018cited by this paper
• From Burnout to Resilience: An Update for Oncologists.

  2018cited by this paper
• CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells

  2018cited by this paper
• Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

  2018cited by this paper
• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

  2018cited by this paper

• Cytoplasmic FKBP7 reflux controls NFE2L1 levels as an adaptive response to chemotherapy in prostate cancer cells

  2026influential citation
• Chemotherapy-Forward Management of Advanced Prostate Cancer: Taxane Timing, Sequencing and the Real-World Place of Immunotherapy.

  2026cites this paper